2023-至今 同济大学医学院，副教授，博导；
2024-至今 同济大学附属上海市第四人民医院，特聘副教授
Medicine School of Tongji University, associate Professor and Ph.D. supervisor；
Shanghai Fourth People's Hospital Affiliated to Tongji University，associate Professor
同济大学医学院副教授，同济大学附属上海市第四人民医院特聘副教授，博导，国家高层次青年人才（原优青）。同济大学和美国Mayo Clinic联合培养博士，主要聚焦代谢介导DNA损伤应答信号通路异常导致肿瘤发生、发展以及治疗抵抗的分子机制，并探索开发靶向抑制DNA修复的小分子多肽，为克服放、疗抵抗提供潜在的治疗靶点和策略。近年，以第一或通讯作者（含共同）身份在 Cell, Molecular Cell, Science Advances, , Journal of Cell biology等期刊上发表多篇SCI论文,申请专利两项，相关研究成果入选年度Cell最佳论文和中国生命科学十大进展。主持科研项目10余项，包括国自然4项，省部级4项，校级2项等，获得国家青年科学基金项目（B类）（原优秀青年科学基金）、上海市浦江人才计划和启明星计划A类等人才项目支持。
An associate professor and doctoral supervisor at the School of Medicine & Shanghai Fourth People's Hospital Affiliated to Tongji University, and a national young talent. His research mainly focuses on the molecular mechanisms by which metabolic - mediated dysregulation of the DNA damage response signaling pathway leads to tumorigenesis, development, and treatment resistance. He also explores the development of small - molecule peptides that target and inhibit DNA repair, providing potential therapeutic targets and strategies for overcoming radiotherapy and chemotherapy resistance. In recent years, as the first or corresponding author (including co-first or co-corresponding), he has published many SCI-indexed papers in journals such as Cell, Molecular Cell, Science Advances, Clinical Cancer Research, Journal of Cell Biology, and Cancer Letters. He has applied for two patents, and his relevant research achievements have been selected as the Best of Cell and one of the top ten scientific advances in life sciences in China. He has presided over more than 10 scientific research projects, including 4 projects from the National Natural Science Foundation of China, 4 provincial-and ministerial-level projects, and 2 university-level projects. He has received support from talent projects such as the National Young Scientists Fund Project (Class B) (formerly the Excellent Young Scientists Fund), the Shanghai Pujiang Talent Program, and the Shanghai Qiming Star Program Class A.
